China Medipharm Insights - Issue No. 32 - January 1999

 

Regular Price: USD 1,000

Special Price USD 700

30% OFF

* Required Fields

Regular Price: USD 1,000

Special Price USD 700

PAY BY INVOICE

Be the first to review this product

Table of Contents

China Medipharm Insights - Issue No. 32 - January 1999, CHINA MEDIPHARM INSIGHTSFEATURE ARTICLENew Healthcare Insurance System to Take Effect in 1999PRODUCT NEWSDomestic Rh-Insulin DevelopedGenetically Engineered Ifn-alpha2b into Formal ProductionSine’s Bifidobacterium Approved by US FDALevonorgestrel Approved by SDADisodium Clodronate to be MarketedPiperacillin Production PermittedBufexamac ProducedSalbutamol Sulfate Marketed Hoechst’s Tritace Approved for ImportationNew Achievement in Transdermal Drug StudiesPatent States of Three Drugs in ChinaAnti-Viral Oral Liquid Approved by US FDAFour Finished TCM Products Approved by US FDAArtificial Cell Healing Membrane DevelopedHOSPITAL DRUG CONSUMPTIONAnalysis of Drug Consumption in Hospitalsin Five Major Chinese Cities Along the Yangtze RiverCOMPANY PROFILEDouble Crane Purchases Three Pharma EnterprisesMeiji Seika Expanding in ChinaRoussel Out of the Chinese Dexamethasone MarketCilag Became Hanjiang’s New PartnerShijiazhuang Pharma Won Bidding for Advertisement On CCTVHeart K Group’s Guannan Factory Starts ConstructionHarbin Pharma Reports 220% Increase in ProfitForeign Pharmaceutical Companies Invest in BeijingBeijing Connect Pharma Commenced ProductionNorth China’s 1-2-16 R&D Plan to be AccomplishedXi’an Bohua Manages Northwest No.2 SyntheticAccord Medicine Distribution Center GSP Innovation ProjectTransgenic Pharma Research Center Passed EvaluationYangzhou Pharma Obtained FDA’s ApprovalLukang Records 880000 Daily Output of Penicillin InjectionsSpiral Algae Processing Company to be EstablishedYantang Pharma Passed GMP CertificationXinhua’s Formulation Institute Commenced OperationYangtze Pharma Passed GMP InspectionZhongjin Pharma GMP Renovation Project StartedSuzhou No.6 Pharma’s Innovation Project Passed InspectionNanyue Pharma Passed GMP InspectionPHARMACEUTICAL MARKETMarket Analysis of Imported DrugsChina’s Chemical Pharmaceutical Industry Shows a Good TrendBULK DRUG EXPORTAnalysis of Bulk Drug Exports at 84th Guangzhou Trade FairNEWS IN BRIEFChina to Set Up OTC Drug System in Early 1999SETC Limits Production of Some DrugsChina’s Pharmaceutical Industry Cherishes the Use of Foreign Capitals1998 SDA Science & Technology Progress Prize WinnersBlood Product Plants Under GMP InspectionsThe Requirements for New Drug Review Committee ExpertsChina’s Drug Supervision System Is ImprovingChronic Disease Patients Rapidly Increase in ChinaCommunity Medical Service Project Started in FujianNew Import Drug Certificate Starts for UseBeijing and Shanghai Strengthen Administration on Special DrugsNew Ways for Medical Care ExploredUniversities and Enterprises Join Hands for R&D of New DrugsHaikou Accelerates the Development of High-Tech Pharma IndustryTCM Export to US Increased 41% in the First HalfChina Cloned Its First Human Disease GeneUnited Lab Fellowship GrantedFirst Novartis - China Symposium ConcludedBethune Medical University Bioengineering Institute EstablishedPharma’s Technical Innovation Loans Available in ZhejiangHeilongjiang Plans a Provincial Investigationon Drug Production Facilities4 Billion Poliomyelitis Vaccines Provided




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.